Adcendo
Adcendo is a clinical-stage biotech company developing antibody-drug conjugate therapies for cancers with high unmet medical need. It has raised $325M in funding and employs 66 people.
The growth story
Adcendo grew from 9 to 66 employees between 2020 and 2026, raising $325M along the way, most recently a Series C in April 2026.
About
Adcendo creates antibody-drug conjugates, a type of cancer therapy that combines antibodies with cytotoxic drugs to target cancer cells. The company focuses on novel targets and optimized drug combinations to develop next-generation treatments.
The company has raised $325M, most recently in a Series C round in 2026. Its 66 employees work primarily in research, with a median tenure of just one year, suggesting rapid team expansion or turnover.
Founders and leadership
Adcendo is led by experienced biopharma executives with a track record of advancing antibody-drug conjugates to approval. Research is the largest function, with 8 employees focused on this area.
The Adcendo org chart
Michael Pehl (CEO) leads 38 mapped leaders with 8 direct reports. Click +N to expand a team; names link to the person’s public profile.
Departments, and which ones grew
Headcount by function: Research 21 (+5% YoY), Business Development 20 (-5% YoY), Healthcare Services 7 (0% YoY), Finance 5 (+25% YoY), Administrative 4 (0% YoY).
Talent flow
Adcendo's team comes primarily from major pharma companies like AstraZeneca, LEO Pharma, and Novo Nordisk, with several also from Rigshospitalet and Genmab. Alumni have moved to roles at Ysios Capital, Saniona, and Zealand Pharma.
Most common previous employers of Adcendo staff: AstraZeneca (7), LEO Pharma (7), Novo Nordisk (7), Rigshospitalet (6), Genmab (5), Københavns Universitet - University of Copenhagen (5). Former Adcendo employees most often moved to Ysios Capital (2), Saniona (1), BiograilTM (1), Zealand Pharma (1), The Danish Association of the Pharmaceutical Industry (1), Telescope Biotech Fund (1).
Alumni worth knowing
Web traffic
Traffic mix: 0% direct, 0% search, 0% social, 0% paid.
What this company is made of
Most common skills at Adcendo: Biotechnology (26), Life Sciences (24), Clinical Trials (23), Oncology (23), Clinical Development (23), Pharmaceutics (22), Drug Development (22), Project Management (18).
Where the team actually sits
Adcendo people are concentrated in Capital Region of Denmark, Denmark (27), Copenhagen Metropolitan Area (5), Denmark (3), United States (2).
Search footprint
Adcendo attracts about 62 organic search visits a month, traffic worth roughly $0K a month if bought through ads. It gained 15 ranking keywords and lost 18 in the last period.
Frequently asked
Adcendo has 66 employees as of September 2026.
Adcendo has raised $325M in total, most recently a Series C round in April 2026.
Adcendo was founded in 2017 by Henrik Stage, Lars Engelholm, Niels Behrendt.
Michael Pehl (CEO) sits at the top of Adcendo's reporting structure, with 8 direct reports.
The most common previous employers of current Adcendo staff are AstraZeneca (7 people), LEO Pharma (7 people), Novo Nordisk (7 people).
Former Adcendo employees most often move to Ysios Capital (2), Saniona (1), BiograilTM (1).
Adcendo attracts about 62 organic search visits a month, worth roughly $0K a month in equivalent ad spend.
The most common skills among Adcendo staff are Biotechnology, Life Sciences, Clinical Trials, Oncology, Clinical Development.
Adcendo staff are concentrated in Capital Region of Denmark, Denmark (27), Copenhagen Metropolitan Area (5), Denmark (3).
Adcendo has about 21 people in Research, up 5% over the past year, as of September 2026.
Adcendo has about 20 people in Business Development, down 5% over the past year, as of September 2026.
Computed from 57 current and 26 former Adcendo profiles, as of September 2026. Source: Crustdata.
Build this for any company
Every number on this page came from the Crustdata API. Point the MCP at a company and get the same org chart, alumni list and talent flow in one prompt.